NCT03015220 - Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

458

Participants

Timeline

Start Date

January 10, 2017

Primary Completion Date

July 12, 2018

Study Completion Date

July 12, 2018

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide

Oral administration once-daily, as add-on to pre-trial oral antidiabetic drug (OAD).

DRUG

Dulaglutide

Subcutaneously administration (s.c., under the skin) once-weekly, as add-on to pre-trial oral antidiabetic drug (OAD).

Trial Locations (34)

123-0845

Novo Nordisk Investigational Site, Adachi-ku, Tokyo

379-0116

Novo Nordisk Investigational Site, Annaka-shi, Gunma

116-0012

Novo Nordisk Investigational Site, Arakawa-ku, Tokyo

260-0804

Novo Nordisk Investigational Site, Chiba-shi, Chiba

104-0061

Novo Nordisk Investigational Site, Chuo-ku, Tokyo

963-8851

Novo Nordisk Investigational Site, Fukushima

373-0036

Novo Nordisk Investigational Site, Gunma

311-0113

Novo Nordisk Investigational Site, Ibaraki

358-0011

Novo Nordisk Investigational Site, Iruma-shi, Saitama

232-0064

Novo Nordisk Investigational Site, Kanagawa

582-0005

Novo Nordisk Investigational Site, Kashiwara-shi, Osaka

350-0851

Novo Nordisk Investigational Site, Kawagoe-shi, Saitama

332-8558

Novo Nordisk Investigational Site, Kawaguchi-shi, Saitama

862-0976

Novo Nordisk Investigational Site, Kumamoto

701-0192

Novo Nordisk Investigational Site, Kurashiki-shi, Okayama

601-1495

Novo Nordisk Investigational Site, Kyoto-shi, Kyoto

181-0013

Novo Nordisk Investigational Site, Mitaka-shi, Tokyo

310-0826

Novo Nordisk Investigational Site, Mito-shi, Ibaraki

880-0034

Novo Nordisk Investigational Site, Miyazaki

569-1045

Novo Nordisk Investigational Site, Osaka

144-0051

Novo Nordisk Investigational Site, Ota-ku, Tokyo

062 0007

Novo Nordisk Investigational Site, Sapporo

004-0004

Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido

980-0021

Novo Nordisk Investigational Site, Sendai-shi, Miyagi

329-0433

Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi

141-0032

Novo Nordisk Investigational Site, Shinagawa-ku, Tokyo

424-0853

Novo Nordisk Investigational Site, Shizuoka-shi, Shizuoka

565-0853

Novo Nordisk Investigational Site, Suita-shi, Osaka

103-0027

Novo Nordisk Investigational Site, Tokyo

104-0031

Novo Nordisk Investigational Site, Tokyo

125-0054

Novo Nordisk Investigational Site, Tokyo

160-0008

Novo Nordisk Investigational Site, Tokyo

171-0021

Novo Nordisk Investigational Site, Toshima-ku, Tokyo

242-0004

Novo Nordisk Investigational Site, Yamato-shi, Kanagawa